Fig. 5From: Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experiencePercentage of patients with chronic migraine, high frequency episodic migraine and low frequency episodic migraine at baseline (T0), and at the end of the third (T1) and of the sixth month (T2) of galcanezumab administrationsBack to article page